Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | ||
| + | |||
| + | ==Diseases for which it is established ''(work in progress)''== | ||
| + | *[[Hepatocellular carcinoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | **[[Esophageal adenocarcinoma]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| − | *[[ | + | *[[Non-small cell lung cancer, EGFR-mutated]] |
| + | *[[Thyroid cancer, differentiated]] | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' YN-968D1 |
*'''Generic name:''' rivoceranib | *'''Generic name:''' rivoceranib | ||
*'''Brand name:''' Aitan | *'''Brand name:''' Aitan | ||
| Line 15: | Line 20: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
| Line 22: | Line 26: | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| − | [[Category:Hepatocellular cancer medications]] | + | [[Category:Hepatocellular carcinoma medications]] |
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Thyroid cancer, differentiated medications]] | ||
| − | [[Category: | + | [[Category:NMPA approved drugs]] |
Latest revision as of 02:08, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is established (work in progress)
Diseases for which it is used
- Esophageal cancer
- Gastric cancer
- Non-small cell lung cancer, EGFR-mutated
- Thyroid cancer, differentiated
Also known as
- Code name: YN-968D1
- Generic name: rivoceranib
- Brand name: Aitan